ArticleThe EPMA journal2026
Dynamic reversibility of biological aging and risk of cardiovascular disease and stroke: a longitudinal cohort study.
Article in The EPMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aging status, indexed by biological age acceleration (BAacc), is closely associated with cardiovascular disease (CVD). However, transitioning from reactive healthcare to predictive, preventive, and personalised medicine (PPPM/3PM) requires elucidating how longitudinal, dynamic transitions in aging status impact incident CVD risk. Methods: We analyzed 4,756 participants from the China Health and Retirement Longitudinal Study. Biological age was calculated using the Klemera-Doubal method (KDM). KDM-BAacc was measured at Wave 1 (baseline) and Wave 3 (follow-up) to derive multidimensional dynamic metrics: change groups, K-means clusters, aging rates, cumulative burden, and extreme phenotypes. Wave 2 was excluded from baseline calculations due to the absence of blood biomarker collection. Incident CVD (stroke and heart disease) was ascertained over a median 9.13-year follow-up. Cox models were adjusted for sociodemographic, lifestyle, and clinical risk factors. Results: Compared to sustained acceleration, reversing aging status ("accelerated to non-accelerated") significantly lowered risks of composite CVD (HR: 0.72, 95% CI: 0.59-0.89) and stroke (HR: 0.46, 95% CI: 0.33-0.64). Consistent protective effects were observed in "high-to-low" cluster trajectories. Conversely, the "Rapid aging" phenotype (sustained highest quartile) nearly doubled stroke risk (HR: 1.97) versus the "Anti-aging" group. Faster aging rates (≥ 1) were associated with a 32% increased stroke risk, demonstrating a linear dose-response relationship. Notably, associations with heart disease were attenuated after adjusting for comorbidities. Conclusions: Biological aging is dynamically reversible, and reversing KDM-BAacc significantly mitigates CVD and stroke risks. For routine medical application, we recommend integrating longitudinal KDM-BAacc profiling into annual primary care check-ups. Crucially, these findings strongly support the paradigm shift from reactive medical services to PPPM/3PM. By identifying reversible suboptimal health prior to disease onset, this predictive tool enables targeted prevention and personalised interventions based on individual aging trajectories, decisively surpassing conventional generalized approaches. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13167-026-00460-9.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.